MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$126,500K
Proceeds from issuance of
common stock under...
$25K
Net cash used in
investing activities
$46,429K
Net cash provided by
financing activities
$25K
Canceled cashflow
$80,071K
Net increase in
cash, cash...
-$18,504K
Canceled cashflow
$46,454K
Accrued expenses and
other current...
$10,142K
Depreciation expense
$5,129K
Other liabilities
$5,000K
Stock-based compensation
expense
$4,219K
Prepaid expenses and
other current assets
-$1,519K
Accounts payable
$497K
Other assets
-$17K
Purchase of marketable
securities
$79,820K
Purchase of property and
equipment
$251K
Net cash used in
operating activities
-$64,958K
Canceled cashflow
$26,523K
Net loss
-$88,409K
Operating lease
liabilities
-$2,612K
Amortization of premiums and
accretion of discounts on...
$389K
Amortization of operating
lease right-of-use...
$71K
Back
Back
Cash Flow
Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. (EIKN)
source: myfinsight.com